Incidence of cardiovascular events in breast cancer patients receiving chemotherapy in clinical practice

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 2, 2008, Pages 125-134

  Sukel, Myrthe P P ^a   Breekveldt Postma, Nancy S ^a   Erkens, Joëlle A ^a   van der Linden, Paul D ^a   Beiderbeck, Annette B ^b   Coebergh, Jan Willem W ^c,d   Herings, Ron M C ^a,d  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c The Netherlands   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Cardiovascular events; Chemotherapy; Incidence rates

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DIGITALIS; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLIC ACID; HEMOSTATIC AGENT; METHOTREXATE; MITOXANTRONE; NITRIC ACID DERIVATIVE; PACLITAXEL; PYRIMIDINE ANTAGONIST; TAXANE DERIVATIVE; TRASTUZUMAB; VINCA ALKALOID;

ADULT; ANGINA PECTORIS; ARTICLE; BREAST CANCER; BREAST SURGERY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HEMOSTATICS; HOSPITALIZATION; HUMANS; INCIDENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TAXOIDS;

EID: 39749127880     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1528     Document Type: Article

References (25)

1. Wilking N, Jonsson B. A Pan-European Comparison Regarding Patient Access to Cancer Drugs. Karolinska Institutet: Stockholm, 2005.
2. Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005; 89: S9-S15.
3. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol 2006; 33: 2-14.
4. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22: 263-302.
5. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention - review of the literature. Med Sci Monit 2000; 6: 411-420.
6. Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005; 5: 233-243.
7. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-1600.
8. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30: 181-191.
9. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-3131.
10. Frishman WH, Sung HM, Yee HC, et al. Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cardiol 1996; 21: 225-286.
11. Hahm S, Dresner HS, Podwall D, et al. DNA biomarkers antecede semiquantitative anthracycline cardiomyopathy. Cancer Invest 2003; 21: 53-67.
12. Beahrs OH, Henson DE, Hutter RVP, et al. (eds). American Joint Committee on Cancer: Manual for staging of cancer. (4th edn). JB Lippincott: Philadelphia, 1992.
13. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20: 3628-3636.
14. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82: 2123-2134.
15. Breslow NE, Day NE. Statistical methods in cancer research, Vol. II: The design and analysis of cohort studies. IARC Scientific Publications No. 82: Lyon, 1989; 69-72.
16. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol 2005; 23: 8597-8605.
17. Eaker S, Dickman PW, Bergkvist L, Holmberg L. Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden. PLoS Med 2006; 3: e25.
18. Houterman S, Janssen-Heijnen ML, Verheij CD, et al. Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer 2004; 90: 2332-2337.
19. Louwman WJ, Janssen-Heijnen ML, Houterman S, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 2005; 41: 779-785.
20. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104-110.
21. Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001; 285: 885-892.
22. Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med 2004; 351: 120-121.
23. Gyenes G. Radiation-induced ischemic heart disease in breast cancer - a review. Acta Oncol 1998; 37: 241-246.
24. Pihkala J, Saarinen UM, Lundstrom U, et al. Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 1996; 32A: 97-103.
25. Pinto BM, Trunzo JJ. Health behaviors during and after a cancer diagnosis. Cancer 2005; 104: 2614-2623.